COVID-19 Pneumonia and Intensive Care Treatment of a Lung Transplant Recipient

Exp Clin Transplant. 2021 Sep 20. doi: 10.6002/ect.2021.0223. Online ahead of print.ABSTRACTIn the COVID-19 pandemic presently affecting the whole world, solid-organ transplant recipients under immunosuppressive therapy are at higher risk than the general population. COVID-19 infection primarily affects the lungs, and so the risk is further increased in lung transplant recipients. The course of COVID-19 in lung transplant recipients is unclear. Here, we present the intensive care follow-up and treatment process of a bilateral lung transplant recipient who developed acute respiratory failure due to COVID-19, for whom the final outcome was favorable. Antiviral treatment was initiated for the 53-year-old male patient with COVID19 pneumonia, and in the following hyperinflammatory phase, high-dose pulse steroid therapy was administered. The patient was followed up with highflow nasal oxygen, and then he was supported by intermittent noninvasive mechanical ventilation as hypoxia became more severe. With these noninvasive ventilation strategies and good intensive care procedures, the patient was successfully discharged.PMID:34546156 | DOI:10.6002/ect.2021.0223

Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - September 21, 2021 Category: Transplant Surgery Authors: Hayriye Cankar Dal Nilg ün Eren Dilek Kazanci Erdal Yekeler Sinan T ürkkan Sema Turan Source Type: research